TABLE 1.
Neutralization profiles of D5 variants
| Profile | D5 IgG variant | ID50 (μg/ml)a | Fold changeb | n |
|---|---|---|---|---|
| Wild-Type | D5 | 48 ± 4.2 | 1.0 | 18 |
| Modestly enhanced (>2.0-fold) | D5_H011_L0 (D5_AR) | 12 ± 2.2 | 4.0 ± 0.78 | 6 |
| D5_H110_L0 | 20 ± 1.9 | 2.7 ± 0.57 | 4 | |
| D5_H101_L0 | 20 ± 8.3 | 2.7 ± 0.34 | 3 | |
| D5_H100_L0 | 31 ± 9.5 | 2.5 ± 0.84 | 2 | |
| D5_H010_L0 | 35 ± 4.8 | 2.5 ± 0.12 | 2 | |
| D5_H000_L1 | 33 ± 2.5 | 2.3 ± 0.78 | 2 | |
| Little to no effect (1.0- to 2.0-fold) | D5_H010_L1 | 42 ± 2.3 | 2.0 ± 0.79 | 3 |
| D5_H111_L0 | 43 ± 9.2 | 1.9 ± 0.41 | 4 | |
| D5_H001_L0 | 54 ± 12 | 1.8 ± 0.36 | 2 | |
| D5_H111_L1 | 62 ± 4.5 | 1.7 ± 0.68 | 3 | |
| D5_H110_L1 | 28 ± 0.07 | 1.4 ± 0.03 | 2 | |
| D5_H011_L1 | 80 ± 4.3 | 1.0 ± 0.06 | 2 | |
| Diminished neutralization (<1.0-fold) | D5_H100_L1 | 100 ± 9.8 | 0.47 ± 0.07 | 2 |
| D5_H101_L1 | >300 | NA | 2 | |
| D5_H001_L1 | >300 | NA | 3 |
a
The ID50 (half maximal inhibitory dose) of each D5 variant is represented by the geometric mean and standard error of the mean from replicate experiments.
b
For each infection assay, the fold enhancement versus D5 was calculated (ID50, D5/ID50, D5 variant); reported fold enhancement is the geometric mean and standard error from replicate experiments. Fold enhancement of >1 corresponds to enhanced neutralization potency (reduced ID50). NA, not applicable.